arrow
B

Ben Tran

Peter MacCallum Cancer Centre
H指数:38
被引数:6,511

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

膀胱内注射cretostimogene grenadenorepvec溶瘤免疫疗法在高风险、BCG难治性、非肌层浸润性膀胱癌伴原位癌(BOND-003队列C):一项单臂、III期临床试验

2026-07-270
PRE
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma

动态免疫特征分析预测寡转移性肾细胞癌对放疗联合抗PD-1疗法的反应

2026-07-080
OAAI
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials

针对寡转移性透明细胞肾细胞癌的转移灶导向治疗: pembrolizumab 联合或单独治疗的两项前瞻性单臂II期试验的合并分析

2026-04-270
PRE
Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies

评估Claudin-6和isochromosome 12p在从生殖细胞癌前病变原位进展至原发性睾丸生殖细胞肿瘤及化疗后畸胎瘤中的作用:对CLDN6靶向治疗的意义

2026-03-130
PRE
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

在接受基于免疫治疗的一线治疗后转移性肾细胞癌(mRCC)中的患者流失率:来自国际mRCC数据库联盟(IMDC)的结果

2026-01-010
PRE
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey

指导晚期尿路上皮癌一线治疗决策:一项全球调查

2025-10-010
OAAI
Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study

原发性难治性转移性肾细胞癌(mRCC)的临床特征、决定因素及后续治疗:一项国际转移数据库联盟(IMDC)研究

2025-10-010
OAAI
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

[177Lu]Lu-PSMA治疗后转移性去势抵抗性前列腺癌患者中的治疗相关髓系肿瘤:一个病例系列

2025-02-201
PRE
CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study

晚期透明细胞肾细胞癌患者的CTX130同种异体CRISPR-Cas9-engineered嵌合抗原受体 (CAR) T细胞: 来自1期COBALT-RCC研究的长期随访和翻译数据

2024-04-051
PRE